0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effect of an Intraventricular Injection of Cyclic AMP on Plasma Prolactin and LH Levels of Ovariectomized, Estrogen-Treated Rats

      , ,

      Neuroendocrinology

      S. Karger AG

      Prolactin, LH, Cyclic AMP, Hypothalamus, Pituitary, PIF

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To evaluate the possible participation of cyclic nucleotidesin the neural control of prolactin and LH release, cannulae were placed in the third ventricle (3rd V) of ovariectomized animals which were treated with estradiol benzoate (Eb) (10 µg, s.c). 48 h after the Eb injection, substances were injected intraventricularly while the rats were lightly anesthetized with ether and their effect on plasma prolactin and LH was determined by radioimmunoassay. The injection of 4 µl of adenosine 3’, 5’-cyclic monophosphate (cAMP) (0.02 or 0.1 M)or its dibutyryl derivative (DBC) (0.1 M)significantly decreased plasma prolactin 30 and/or 60 min later. The response to cyclic AMP was not potentiated by theophylline. Four µl of the 0.9% NaCl diluent, adenosine 5’-monophosphate (5’ AMP) (0.1 M)or theophylline (0.02 or 0.04 M)failed to alter plasma prolactin. DBC injected bilaterally into the anterior pituitary (AP) (2 µl into each lobe, 0.05 or 0.1 M)did not decrease plasma prolactin, contrasting with the effect observed after its 3rd V injection. When the volume for intraventricular injections was increased, 10 µl of 0.9% NaCl slightly increased the prolactin concentration, but 10 µl of theophylline (0.02 M)plus cyclic AMP (0.1 M)prevented the increase, and 10 µl of theophylline (0.04 M)alone induced a significant decline in prolactin. None of these treatments altered plasma LH levels. DBC (0.1 M, 10 µl) injected along with theophylline significantly depressed prolactin at 30 and 60 min post-injection and failed to alter plasma LH in 5 animals; however this treatment induced marked behavioral and autonomic changes in 7 animals and these changes were associated with increased plasma LH and prolactin 30 min after injection. The results suggest that cyclic AMP may be involved in the hypothalamic control of prolactin secretion by modifying the output of prolactin inhibiting factor (PIF) and/or releasing factor (PRF) to decrease prolactin release. The

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1974
          1974
          20 March 2008
          : 16
          : 5-6
          : 342-354
          Affiliations
          Department of Physiology, University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, Tex.
          Article
          122580 Neuroendocrinology 1974;16:342–354
          10.1159/000122580
          4375263
          © 1974 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 13
          Categories
          Paper

          Comments

          Comment on this article